MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7

  • Authors:
    • Xiaofeng Tang
    • Weigang Yang
    • Zheyue Shu
    • Xiaodong Shen
    • Weichen Zhang
    • Chao Cen
    • Linping Cao
    • Min Zhang
    • Shusen Zheng
    • Jun Yu
  • View Affiliations

  • Published online on: December 6, 2018     https://doi.org/10.3892/or.2018.6908
  • Pages: 1231-1237
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is a globally prevalent malignancy associated with a poor patient prognosis. We investigated the relationship between microRNA‑223 (miR‑223) expression and the sensitivity of HCC cells to sorafenib treatment. miR‑223 expression was determined in HCC cell lines with differential sorafenib sensitivity using reverse transcription‑quantitative PCR. miR‑223 inhibitor, miR‑223 mimic, and F‑box and WD repeat domain‑containing 7 (FBW7) short interfering RNAs (siRNAs) were transfected into the HCC cells to regulate the expression levels of miR‑223 and FBW7. Cell proliferation was evaluated using an ethynyl deoxyuridine (EdU) incorporation assay and Cell Counting Kit‑8. FBW7 protein expression levels were observed using western blotting. miR‑223 expression was increased in the HCC cells with sorafenib resistance. HCC cells with miR‑223 knockdown had significantly increased sorafenib sensitivity, but the miR‑223 mimic had the opposite effect. The TargetScan web server predicted that FBW7 is a target of miR‑223, which was confirmed by western blotting. Furthermore, FBW7 siRNA transfection increased HCC cell resistance to sorafenib in an obvious manner, and entirely eliminated the effect of the miR‑223 inhibitor on enhancing sorafenib sensitivity. To conclude, miR‑223 expression is upregulated in sorafenib‑resistant HCC cells, and miR‑223 knockdown significantly enhances HCC cell sensitivity to sorafenib by increasing expression of the target gene, FBW7, suggesting that miR‑223 may be a new therapeutic target for overcoming sorafenib resistance.

References

1 

Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al: Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Njei B, Rotman Y, Ditah I and Lim JK: Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 61:191–199. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH and Mohammed K: Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 67:422–435. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, et al: Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol. 18:1624–1636. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Kanthaje S, Makol A and Chakraborti A: Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. Hepatol Res. 48:5–14. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Axtell MJ, Westholm JO and Lai EC: Vive la différence: Biogenesis and evolution of microRNAs in plants and animals. Genome Biol. 12:2212011. View Article : Google Scholar : PubMed/NCBI

10 

Lu J and Clark AG: Impact of microRNA regulation on variation in human gene expression. Genome Res. 22:1243–1254. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Berasain C: Hepatocellular carcinoma and sorafenib: Too many resistance mechanisms? Gut. 62:1674–1675. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Gauthier A and Ho M: Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Zhu YJ, Zheng B, Wang HY and Chen L: New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Davidson-Moncada J, Papavasiliou FN and Tam W: MicroRNAs of the immune system: Roles in inflammation and cancer. Ann NY Acad Sci. 1183:183–194. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Dong J, Liu Y, Liao W, Liu R, Shi P and Wang L: miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma. J Bone Oncol. 5:74–79. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Streppel MM, Pai S, Campbell NR, Hu C, Yabuuchi S, Canto MI, Wang JS, Montgomery EA and Maitra A: MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res. 19:4067–4078. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H: Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, Peng L, Sun J and Chen Z: miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol. 48:1855–1867. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Xu Y, Sengupta T, Kukreja L and Minella AC: MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Minella AC and Clurman BE: Mechanisms of tumor suppression by the SCFFbw7. Cell Cycle. 4:1356–1359. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2019
Volume 41 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tang, X., Yang, W., Shu, Z., Shen, X., Zhang, W., Cen, C. ... Yu, J. (2019). MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7. Oncology Reports, 41, 1231-1237. https://doi.org/10.3892/or.2018.6908
MLA
Tang, X., Yang, W., Shu, Z., Shen, X., Zhang, W., Cen, C., Cao, L., Zhang, M., Zheng, S., Yu, J."MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7". Oncology Reports 41.2 (2019): 1231-1237.
Chicago
Tang, X., Yang, W., Shu, Z., Shen, X., Zhang, W., Cen, C., Cao, L., Zhang, M., Zheng, S., Yu, J."MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7". Oncology Reports 41, no. 2 (2019): 1231-1237. https://doi.org/10.3892/or.2018.6908